BioSpace News Archive

exoSTING is engineered to provide targeted delivery of Codiak’s proprietary STING agonist to antigen presenting cells in the tumor microenvironment

Korro Bio strengthens board of directors with appointment of industry leader, Omar Khwaja, M.D., Ph.D.

Funding Will Support Clinical Trials to Evaluate the Company’s Novel Treatment for Peripheral Artery Disease

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced the addition of Barry Greene to the company’s board of directors.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced that it plans to release its third quarter 2020 financial results on Tuesday, October 27, 2020.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has entered into an agreement with Keystone Capital Partners (“Keystone”) for a preferred stock investment of US$7.0 Million. Additional details on the transaction are outlined in the accompanying Registration Statement filed on September 30, 2020 (Fil

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in the company’s Phase 2/3 clinical trial evaluating ATH-1017, a once-daily investigational drug for the trea

Supporting the Company’s Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company demonstrates solidity of its business model with banks joining in the round - Didier Hirsch, former CFO at Agilent, joins the company’s Board of Directors a

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first pa

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX® System. The data generated from